Zymeworks (US:ZYME) — Company Overview, News & Financial Data
Zymeworks is a biotherapeutics company focused on multifunctional therapies for cancer and autoimmune diseases.
About Zymeworks
Zymeworks (NYSE:ZYME) is a biotherapeutics company focused on the development and commercialization of next-generation multifunctional biotherapeutics, designed to improve patient outcomes in cancer and autoimmune diseases. The company is versatile in its approach, engaging in the discovery, development, and commercialization of innovative protein-based therapeutics. Zymeworks' projects center around its proprietary platforms which enhance the efficacy and safety of therapeutic antibodies and antibody-drug conjugates. A key objective for Zymeworks is to advance its pipeline of preclinical and clinical candidates, with the ultimate goal of delivering groundbreaking treatments to patients in need.
Snapshot
Operations
Products and/or services of Zymeworks
- Zymeworks' lead product, zanidatamab, is a bispecific antibody targeting HER2 for various cancers.
- The company developed ZW49, a bispecific antibody-drug conjugate for treating HER2-expressing cancers.
- ZYME-83 is a preclinical project aimed at addressing solid tumors through innovative molecular targeting.
- The Azymetric platform enables the development of bispecific and multispecific antibodies for diverse therapeutic applications.
- Zymeworks' Effector Function Enhancement and Control Technology (EFECT) portfolio facilitates the modulation of immune cell interactions.
- Their Immune Modulating Drug Conjugates (IMDCs) technology is designed to enhance the delivery and efficacy of immunotherapies.
Zymeworks executive team
- Mr. Kenneth H. Galbraith C.A.Chairman of the Board, CEO & President